Marcella Origgi (PhD) is the Chief Executive Officer of Valo Therapeutics. She brings extensive experience across immunology, oncohematology, rare inherited diseases, precision medicine and advanced therapy medicinal products (ATMPs).
Dr Andrew Dean, Board Member, completed his medical training in the UK, became a fellow of the Royal Australian College of Physicians in 1993. He established the palliative care services at Sir Charles Gairdner Hospital and St John of God Subiaco in Perth, later becoming professor of palliative medicine at Edith Cowan University Western Australia.
David is an experienced executive in the ASX listed environment.
Associate Professor Paul Porter (MBBS, FRACP), Director, is the founder of Freeman Road Pty Ltd, an Australian company that specialises in early stage biomedical investments with an emphasis on global research and development collaborations. Freeman Road has investments in companies across Australia, South East Asia, Europe and the USA.